T16 Phase I studies – Phase I units and you, a Phase I unit’s expectation – A Day in the Life of a Phase I Study Coordinator Jeffery Wong, Clinical Research.

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
Tips to a Successful Monitoring Visit
Chicken Soup for the Busy Coordinator
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
David Cloutier Director, Research Center Management and Development Budgeting for Industry Sponsored Clinical Trials.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Monitoring and Auditing
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Developed by Klinikos; Roy Fraser (2012) Investigator Study File
Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.
Determining % Effort for Clinical Trial Kathy Price, RN, MBA Manager, GI Clinical Research.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Study Team Members and Responsibilities Chicken Soup for the Busy Coordinator (April 2010)
Using EDC-Rave to Conduct Clinical Trials at Genentech
MODULE A:MODULE A: Introduction to the CRA/CRC RolesIntroduction to the CRA/CRC Roles Jane FendlJane Fendl March 24, 2010March 24, Version: Final.
PRE-AWARD PAPERWORK FOR CLINICAL TRIALS SERIES 4, SESSION 8 OCTOBER 28, 2014 Applicants and Administrators Pre-Award Luncheon Series.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Clinical Data Management is involved in all aspects of processing the clinical data, working with a range of computer applications, database systems.
Overview of Good Clinical Practices (GCPs)
Clinical Trial Infrastructure in Centres Lillian L. Siu Princess Margaret Hospital.
M ODULE H I NTERIM M ONITORING V ISIT Denise Thwing 21 Apr Version: Final 21-Apr-2010.
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Yesterday, today, and tomorrow
Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
Planning and Surviving An Audit/Monitoring visit Carmen B. Jacobs, BS, RN,OCN, CCRP U.T. MD Anderson Cancer Center Houston, Texas U.S.A.
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
Investigational New Drug Application (IND)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
SMART Study Closeout Washington ICC Meeting 03 June 2007.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Using EDC-Rave to Conduct Clinical Trials at Genentech Susanne Prokscha Principal CDM PTM Process Analyst February 2012.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Site Monitoring Shirley Frederiksen Donna Harsh.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Research Documentation Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic Compliance, Corporate Compliance.
IRB BASICS BETTY WILSON, MS, CIP. CONCEPTS SUBMISSION APPROVAL RECRUITING WORKING WITH PRINCIPAL INVESTIGATOR (PI) /SPONSOR POLICIES DEVIATIONS RECORD.
GCP (GOOD CLINICAL PRACTISE)
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Supervisory Responsibilities of Clinical Investigators
Design of Case Report Forms
PRCSG Training Webinar: Budget for Industry Sponsored Studies
The Role and Responsibilities of the Clinical Research Coordinator
Responsibilities of Sponsor, Investigator and Monitor
Training Requirements for PI and Research Staff
What is a Data and Safety Monitoring Plan and how do I get one?
Data Managers’ Forum What’s in it for us?
CLINICAL DATA MANAGEMENT
Society for Clinical Trials 37th Annual Meeting 2016
ARCADIA Coordinator Webinar
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
EPIC Tools for Clinical Research
Clinical Trial Budgets
PEARLS Overview and Research Team Management
EPIC Tools for Clinical Research
Presentation transcript:

T16 Phase I studies – Phase I units and you, a Phase I unit’s expectation – A Day in the Life of a Phase I Study Coordinator Jeffery Wong, Clinical Research Coordinator, Nucleus Network Ltd

A Day in The Life of A Study Coordinator Main objectives: –To create awareness and a better understanding of a Phase I clinical research co-ordinator’s (CRC) role –To provide an understanding of the intensity of Phase I clinical trials –To highlight some of the differences between Phase I trials and later phase trials

A Day in The Life of A Study Coordinator Clinical Research Co-ordinator Principal Investigator Ethics Committee Technical/ Study Logistics Recruitment/ Screening Clinical Trials Pharmacy Data Management Subjects/ Participants Commercial Sponsor

A Day in The Life of A Study Coordinator Principal Investigator Report and discuss any adverse events as well as any subject safety concerns. - Daily updates if conducting MAD study Provide PI with periodic update on study progress. Ethics Committee Prepare ethics submission package in conjunction with Project Manager Provide safety updates, submit amendments and obtain approvals. i.e. fortnightly safety reports. Provide annual progress reports.

A Day in The Life of A Study Coordinator Commercial Sponsor Provide updates to Sponsor/CRA pertaining to recruitment and progress of study. Clarify specific protocol requirements i.e. inclusion/exclusion criteria, study procedures. Confirm timeline for DSMB and the data required for evaluation. DSMB meetings could be fortnightly. Provide daily AE and safety lab updates via . SAE reporting.

A Day in The Life of A Study Coordinator Recruitment/Screening Ensure adequate subjects are recruited for each study including availability of alternate subjects. Up to 4 – 6 volunteers being screened daily Average screening window is 28 days Ensure exclusion/inclusion criteria are clear to minimise ratio of screen failures. Patient/Subject Ensure subjects’ compliance and their understanding of each study’s requirements. Ensure subjects’ safety and comfort whilst participating in a study i.e. laundry, catering, entertainment etc.

A Day in The Life of A Study Coordinator Technical/Study Logistics Ensure study related samples i.e. PK, PD and PGx are appropriately processed and shipped to specified destination as indicated in study protocol. Shipment could occur on the same day after last sample is collected. Liaise with technical lead to ensure study laboratory requirements are adequate. Liaise with other contracted laboratories i.e. Melbourne Path, Alfred Path etc. Short turnaround time for results.

A Day in The Life of A Study Coordinator Clinical Trials Pharmacy Provide prescriptions to Clinical Trials Pharmacy for dispensing of IP –Dispensing of IP could take place on the morning of dosing. Ensure proper destruction/return of IP post dosing – IP accountability. Data Management Ensure completeness of source documentation. Ensure CRF transcription is performed in a timely manner in accordance with pre-defined timelines. Ensure open queries are resolved.

A Day in The Life of A Study Coordinator Scenario Study 1: Dosing Day Very intense with all activities running by the clock. –Triplicate ECGs, Supine/Seated/Standing vitals, multiple blood sampling time points Every team member needs to know their role and be on stand by to provide assistance. Every change in circumstances result in a chain reaction i.e. delay in dosing. Food effect trials have additional concerns i.e. meal times & type of food. Sponsors may witness dosing or require verbal updates on day of dosing.

A Day in The Life of A Study Coordinator Day BREAKFAST7:007:207:408:008:208:40 Chest Auscultation7:107:307:508:108:308:50 IOP Assessment7:157:357:558:158:358:55 Subject Supine/Remove water7:207:408:008:208:409:00 Predose Vitals/Oximetry7:237:438:038:238:439:03 Predose ECG7:267:468:068:268:469:06 LFT Assessment7:307:508:108:308:509:10 End of Predose PK urine7:357:558:158:358:559:15 Predose PK/ Safety7:508:108:308:509:109:30 End of Dose 18:208:409:009:209:4010:00 (IPD) PK BloodIPD (IPD) OximetryIPD 5min PK Bood8:258:459:059:259:4510:05 10min PK Blood8:308:509:109:309:5010:10 15min Chest Auscultation/AE Check8:328:529:129:329:5210:12 15min Oximetry8:338:539:139:339:5310:13 15min PK Blood8:358:559:159:359:5510:15 Subject Supine8:378:579:179:379:5710:17 30min ECG8:409:009:209:4010:0010:20 30min LFT Assessment8:459:059:259:4510:0510:25 30min PK Blood8:509:109:309:5010:1010:30 1hr Chest Auscultation9:109:309:5010:1010:3010:50 Subject Supine9:129:329:5210:1210:3210:52 1hr Vitals Signs/AE Check9:159:359:5510:1510:3510:55 1hr ECG9:179:379:5710:1710:3710:57 1.0hr PK Blood9:209:4010:0010:2010:4011:00 1.0hr LFT Assessment9:259:4510:0510:2510:4511:05 1.5hr PK Blood9:5010:1010:3010:5011:1011:30 Subject Supine10:1410:3410:5411:1411:3411:54 2.0hr ECG10:1710:3710:5711:1711:3711:57 2.0hr PK Blood/AE Check10:2010:4511:0511:2511:4512:05 2.5hr PK Blood10:5011:1011:3011:5012:1012:30 Subject Supine11:1411:3411:5412:1412:3412:54 3.0hr ECG11:1711:3711:5712:1712:3712:57 3.0hr PK Blood11:2011:4012:0012:2012:4013:00 3.5hr PK Blood11:5012:1012:3012:5013:1013:30 Subject Supine12:1112:3112:5113:1113:3113:51 4.0hr Vital Signs/AE Check12:1412:3412:5413:1413:3413:54 4.0hr ECG12:1712:3712:5713:1713:3713:57 4.0hr PK /Safety Blood12:2012:4013:0013:2013:4014:00 IOP Assessment12:2512:4513:0513:2513:4514:05 LUNCH12:3012:5013:1013:3013:5014:10 Fig 1. Study Task Pad

A Day in The Life of A Study Coordinator Day BREAKFAST7:007:207:408:008:208:40 Chest Auscultation7:107:307:508:108:308:50 IOP Assessment7:157:357:558:158:358:55 Subject Supine/Remove water7:207:408:008:208:409:00 Predose Vitals/Oximetry7:237:438:038:238:439:03 Predose ECG7:267:468:068:268:469:06 LFT Assessment7:307:508:108:308:509:10 End of Predose PK urine7:357:558:158:358:559:15 Predose PK/ Safety7:508:108:308:509:109:30 End of Dose 18:208:409:009:209:4010:00 (IPD) PK BloodIPD (IPD) OximetryIPD 5min PK Bood8:258:459:059:259:4510:05 10min PK Blood8:308:509:109:309:5010:10 15min Chest Auscultation/AE Check8:328:529:129:329:5210:12 15min Oximetry8:338:539:139:339:5310:13 15min PK Blood8:358:559:159:359:5510:15 Subject Supine8:378:579:179:379:5710:17 30min ECG8:409:009:209:4010:0010:20 30min LFT Assessment8:459:059:259:4510:0510:25 30min PK Blood8:509:109:309:5010:1010:30 1hr Chest Auscultation9:109:309:5010:1010:3010:50 Subject Supine9:129:329:5210:1210:3210:52 1hr Vitals Signs/AE Check9:159:359:5510:1510:3510:55 1hr ECG9:179:379:5710:1710:3710:57 1.0hr PK Blood9:209:4010:0010:2010:4011:00 1.0hr LFT Assessment9:259:4510:0510:2510:4511:05 1.5hr PK Blood9:5010:1010:3010:5011:1011:30 Subject Supine10:1410:3410:5411:1411:3411:54 2.0hr ECG10:1710:3710:5711:1711:3711:57 2.0hr PK Blood/AE Check10:2010:4511:0511:2511:4512:05 2.5hr PK Blood10:5011:1011:3011:5012:1012:30 Subject Supine11:1411:3411:5412:1412:3412:54 3.0hr ECG11:1711:3711:5712:1712:3712:57 3.0hr PK Blood11:2011:4012:0012:2012:4013:00 3.5hr PK Blood11:5012:1012:3012:5013:1013:30 Subject Supine12:1112:3112:5113:1113:3113:51 4.0hr Vital Signs/AE Check12:1412:3412:5413:1413:3413:54 4.0hr ECG12:1712:3712:5713:1713:3713:57 4.0hr PK /Safety Blood12:2012:4013:0013:2013:4014:00 IOP Assessment12:2512:4513:0513:2513:4514:05 LUNCH12:3012:5013:1013:3013:5014:10 Fig 1. Study Task Pad

A Day in The Life of A Study Coordinator Scenario Study 2: Source notes documentation Multiple data points due to assessment intensity. –100 – 200 data points from predose to 1 st hr post dose. Documentation involves entry from multiple study personnel (entire study team). Medical history and concomitant medication records are usually brief compared to later phase trials i.e. several volumes.

A Day in The Life of A Study Coordinator Fig 2. Source Notes

A Day in The Life of A Study Coordinator Fig 2. Source Notes

A Day in The Life of A Study Coordinator Scenario Study 3: Data Management QC performed on source documentation prior to being monitored. More and more sponsors are requesting real time data entry. CRA may need to come in and perform SDV whilst data is being entered into the CRFs. Lab results are transferred electronically – dose escalation evaluation. Tight timeline for query resolution before data base lock.

A Day in The Life of A Study Coordinator Conclusion Men can multitask too! Old myth is busted. The success/smooth running of an early phase trial relies heavily on team effort hence clear communication line is imperative. Early phase trials are intense hence study protocol clarity is essential to ensure expectations could be met. Main differences between Phase I trials and later phase trials are the intensity and study timelines.